U.S. solidifies goals for home COVID-19 testing via $231.8M  contract with Ellume

Having named home COVID-19 testing among the many goals in its COVID-19 plan, the Biden administration is backing up the aspiration via a $231.8 million deal with rapid antigen test developer Ellume.

The funds will enable the Australian company to build a U.S. manufacturing facility, ramping up its production capacity from 200,000 to about 700,00 tests per day. As part of the agreement with the U.S. Department of Defense (DOD) and HHS, Ellume will deliver 8.5 million tests to support the country’s National Strategy for the COVID-19 Response and Pandemic Preparedness...